BMS, Ono expand cancer immunotherapy pact
This article was originally published in Scrip
Bristol-Myers Squibb and Ono Pharmaceuticals are joining up under a collaborative deal to develop a number of immunotherapies for various cancer indications in Japan, South Korea and Taiwan.
You may also be interested in...
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.